Placeholder image

Robert LütjensHead of Discovery

Dr Lütjens is responsible for all biology activities and has extensive experience in drug discovery. He established the biology capabilities and built the company’s small molecule allosteric modulator biology platform. He played a pivotal role in the success of both internal and partnered programs, including the discovery of dipraglurant and ADX71149, both of which progressed into phase II clinical development. Under the biology leadership of Dr Lütjens, Addex team also discovered ADX71441, which was recently licensed to Indivior PLC. Prior to joining Addex at inception in 2002, Dr Lütjens completed a postdoctoral fellowship in the Department of Neuropharmacology at the Scripps Research Institute, in La Jolla, CA, where he focused on understanding molecular changes involved in addiction disorders. Dr Lütjens obtained his degrees in Biology from the University of Geneva, his master’s at the Swiss Institute for Experimental Cancer Research and his Ph.D. thesis at the Glaxo Institute for Molecular Biology in Geneva and the Institute for Cellular Biology and Morphology in Lausanne. Dr. Lütjens is co-author of over 30 peer-reviewed publications and patents.